Aldeyra Therapeutics, Inc. (NASDAQ: ALDX ) is a biotechnology company that develops medicines with a novel anti-inflammatory approach. They basically leverage their proprietary Reactive Aldehyde Species [RASP] platform. ALDX's lead asset is Reproxalap for Dry Eye Disease [DED] and Allergic Conjunctivitis [AC]. However, for DED, their regulatoryMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M. ...